AbbVie Licenses ProBioGen’s GlymaxX Technology

ProBioGen has signed a commercial license agreement with AbbVie to apply ProBioGen's GlymaxX technology to boost the antibody-dependent cell-mediated cytotoxicity (ADCC).

The GlymaxX technology for production of afucosylated proteins is universally applicable, simple and potent, according to the company. A single GlymaxX modified cell line is sufficient to produce both, completely fucosylated or afucosylated antibodies and those with an intermediate defined fuscosylation level. The technology can be integrated in newly developed or already existing cell lines of different origins.

ProBioGen is a Berlin-based CDMO for developing and manufacturing complex therapeutic glycoproteins.